down arrow

Altimmune, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02155H2004
USD
5.31
0.55 (11.55%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.005.46

52 Week

2.9010.11
Valuation
Technical
Day's Volume

CASH

3.11 M

Shareholding (Mar 2025)

FII

12.82%

Held by 89 FIIs

DII

65.61%

Held by 27 DIIs

Promoter

0.14%

How big is Altimmune, Inc.?

22-Jun-2025

As of Jun 18, Altimmune, Inc. has a market capitalization of 558.83 million and reported net sales of 0.04 million with a net profit of -90.23 million over the latest four quarters. As of Dec 24, shareholder's funds were 123.51 million and total assets were 139.31 million.

As of Jun 18, Altimmune, Inc. has a market capitalization of 558.83 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.04 million, while the sum of net profit for the same period is -90.23 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 123.51 million and total assets of 139.31 million.

Read More

What does Altimmune, Inc. do?

22-Jun-2025

Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on developing immune response products for disease prevention and treatment. As of March 2025, it has a market cap of $558.83 million, with net sales of $0 and a net loss of $20 million.

Overview: <BR>Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on developing products that stimulate robust and durable immune responses for the prevention and treatment of disease, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 558.83 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.05 <BR>Return on Equity: -63.48% <BR>Price to Book: 3.93<BR><BR>Contact Details: <BR>Address: 910 Clopper Rd Ste 201S, GAITHERSBURG MD: 20878-1361 <BR>Tel: ['1 240 6541450', '1 617 7755956'] <BR>Fax: 1 302 6745266 <BR>Website: https://altimmune.com/

Read More

Who are in the management team of Altimmune, Inc.?

22-Jun-2025

As of March 2022, the management team of Altimmune, Inc. includes Dr. Mitchel Sayare (Chairman), Dr. Vipin Garg (CEO), Dr. Diane Jorkasky, Dr. David Drutz, Mr. John Gill, Mr. Philip Hodges, and Mr. Wayne Pisano (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Altimmune, Inc. includes the following individuals:<BR><BR>- Dr. Mitchel Sayare, Chairman of the Board<BR>- Dr. Vipin Garg, President, Chief Executive Officer, and Director<BR>- Dr. Diane Jorkasky, Director<BR>- Dr. David Drutz, Independent Director<BR>- Mr. John Gill, Independent Director<BR>- Mr. Philip Hodges, Independent Director<BR>- Mr. Wayne Pisano, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Altimmune, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2023, Altimmune, Inc. is considered overvalued with a significant downgrade in investment appeal due to high financial metrics and negative returns compared to its peers, despite a recent stock return of 22.42%.

As of 28 February 2023, the valuation grade for Altimmune, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 3.21 and an EV to Sales ratio of 306.20, which are markedly high compared to industry standards. Additionally, the negative ROE of -63.48% and the negative EV to EBIT and EV to EBITDA ratios further underscore the company's financial struggles.<BR><BR>In comparison to its peers, Altimmune, Inc. exhibits a less favorable position, with Harpoon Therapeutics, Inc. showing a P/E of -28.51 and Graphite Bio, Inc. at -16.68, both of which are also classified as does not qualify. This suggests that Altimmune's valuation is not only high relative to its own financial performance but also compared to similar companies in the sector. Despite a recent positive stock return of 22.42% over the past month, the overall financial indicators suggest that Altimmune, Inc. remains overvalued in the current market context.

Read More

Is Altimmune, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Altimmune, Inc. is in a bearish trend with mixed signals, showing a year-to-date return of -46.32% compared to the S&P 500's 12.22%, despite some potential for recovery indicated by the monthly RSI.

As of 1 July 2025, the technical trend for Altimmune, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength indicated by the weekly MACD being mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly timeframe but is bullish monthly, suggesting some potential for recovery. However, the moving averages are mildly bearish on the daily timeframe, and both the KST and Bollinger Bands indicate bearish conditions on the weekly and monthly timeframes.<BR><BR>In terms of performance, Altimmune has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.32% versus the S&P 500's 12.22%, and a one-year return of -47.91% compared to 17.14% for the index. Overall, the bearish trend is supported by the prevailing indicators, despite some mixed signals in shorter timeframes.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 327 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.04

stock-summary
Return on Equity

-54.38%

stock-summary
Price to Book

2.03

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
44.29%
0%
44.29%
6 Months
-2.03%
0%
-2.03%
1 Year
-39.59%
0%
-39.59%
2 Years
48.74%
0%
48.74%
3 Years
-52.93%
0%
-52.93%
4 Years
-43.99%
0%
-43.99%
5 Years
-58.61%
0%
-58.61%

Altimmune, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Altimmune, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Altimmune, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength indicated by the weekly MACD being mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly timeframe but is bullish monthly, suggesting some potential for recovery. However, the moving averages are mildly bearish on the daily timeframe, and both the KST and Bollinger Bands indicate bearish conditions on the weekly and monthly timeframes. In terms of performance, Altimmune has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.32% versus the S&P 500's 12.22%, and a one-year return of -47.91% compared to 17.14% for the index. Overall, the bearish trend is supported by the prevailing indicators, despite some mixed signals in shorter timeframes....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-65.60%
EBIT Growth (5y)
-209.13%
EBIT to Interest (avg)
-76.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
73.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.21
EV to EBIT
-3.12
EV to EBITDA
-3.12
EV to Capital Employed
-41.04
EV to Sales
306.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-63.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 43 Schemes (21.42%)

Foreign Institutions

Held by 89 Foreign Institutions (12.82%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -12.76% vs 15.52% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.90",
          "val2": "-21.80",
          "chgp": "-5.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.10",
          "val2": "-19.60",
          "chgp": "-12.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,584,400.00%",
          "val2": "-4,363,000.00%",
          "chgp": "-22,140.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 500.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.58% vs -4.37% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.90",
          "val2": "-83.00",
          "chgp": "-23.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-12.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-95.10",
          "val2": "-88.40",
          "chgp": "-7.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,158,600.00%",
          "val2": "-196,032.90%",
          "chgp": "-4,96,256.71%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.90
-21.80
-5.05%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-22.10
-19.60
-12.76%
Operating Profit Margin (Excl OI)
-4,584,400.00%
-4,363,000.00%
-22,140.00%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -12.76% vs 15.52% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.40
-100.00%
Operating Profit (PBDIT) excl Other Income
-102.90
-83.00
-23.98%
Interest
0.00
0.00
Exceptional Items
0.00
-12.40
100.00%
Consolidate Net Profit
-95.10
-88.40
-7.58%
Operating Profit Margin (Excl OI)
-5,158,600.00%
-196,032.90%
-4,96,256.71%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 500.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.58% vs -4.37% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Altimmune, Inc. stock-summary
stock-summary
Altimmune, Inc.
Pharmaceuticals & Biotechnology
Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
Company Coordinates stock-summary
Company Details
910 Clopper Rd Ste 201S , GAITHERSBURG MD : 20878-1361
stock-summary
Tel: 1 240 65414501 617 7755956
stock-summary
https://altimmune.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."